Research Article

Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients

Mohammad Mahdi Shahpouri 1, Majid Barekatain 2, Mahgol Tavakoli 3, Omid Mirmosayyeb 1, Ali Safaei 1, and Vahid Shaygannejad 1

1 Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Psychology, School of Educational Sciences and Psychology, University of Isfahan, Isfahan, Iran

Correspondence should be addressed to Vahid Shaygannejad; v.shaygannejad@gmail.com

Received 9 August 2020; Revised 29 September 2020; Accepted 7 November 2020; Published 23 November 2020

Academic Editor: Vincenzo Di Lazzaro

Copyright © 2020 Mohammad Mahdi Shahpouri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that affects cognitive performance and leads to depression and decreased quality of life (QOL). The current study aims to assess the effects of cognitive rehabilitation versus donepezil therapy on memory, attention, depression, and QOL in MS patients compared to placebo and control groups.

Methods. Eighty MS patients were randomly selected from parallel randomized trials and divided into four groups: A: cognitive rehabilitation (10 sessions of 120 minutes), B: control (no intervention), C: donepezil (10 mg daily), and D: placebo. Patients received the intervention for three months. They were assessed for cognitive status, depression, and QOL prior to the intervention and immediately after that using abbreviated mental test (AMT), prospective and retrospective memory questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span, MSQOL-54, and second edition Beck depression inventory (BDI). We compared scores between groups after the intervention, as well as the progression of scores in every single group.

Results. The cognitive rehabilitation group showed improvement in EMQ, RPMQ, digit span, physical and mental health subscales of MSQOL-54, and depression ($P < 0.05$). We observed the same effect for donepezil except for the digit span test ($P = 0.15$). Intergroup comparison of scores showed the superiority of cognitive rehabilitation over donepezil in digit span, depression, and mental health scores. Conclusion. Both donepezil and cognitive rehabilitation effectively improve memory performance, attention, depression, and QOL in MS patients. Cognitive rehabilitation is superior altogether. This study is registered with the Iranian registry of clinical trials http://clinicaltrials.gov/ct2/show/IRCT2016042227522N1.

1. Introduction

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that involves the central nervous system (CNS) and leads to the formation of focal lesions [1]. MS predominantly occurs in young females and causes a variety of physical, mental, and psychological disturbances that affect patients’ life considerably [2, 3]. Memory, attention, performance, and processing speed are among the affected cognitive areas [4]. These disturbances added to the chronic nature of MS and patients’ impaired motor function pose depression in affected individuals [5, 6]. Altogether, the patients’ social, individual, and occupational lives will be affected and their quality of life (QOL) will get deteriorated [7].

Pharmacological interventions to improve cognitive impairment in MS patients are hardly investigated with conflicting findings. Donepezil, an acetylcholine esterase inhibitor (AChEI), is a neuroprotective drug used widely in the treatment of Alzheimer’s Disease [8]. Moreover, it is an agonist of sigma receptors that can be used in the treatment of cognitive impairment [9]. Donepezil therapy has been
associated with improved learning and memory function among MS patients in a previous study [10]. However, no superiority of donepezil over placebo has been observed in a larger multicenter study with regard to verbal memory [11].

On the other hand, cognitive rehabilitation has been suggested in affected MS patients more recently. In this technique, patients are trained to utilize more effective defensive mechanisms and give up impaired mechanisms to deal with their disabilities and worsened function [12]. The effect of cognitive rehabilitation on MS patients has been investigated in several studies with different designs and methodologies. While most previous investigators have focused on one or two cognitive domains, a few have utilized a more general approach [7]. Other differences include variations in intervention duration and frequency, utilizing a similar approach for all patients or tailoring them with respect to the individual’s impairments, and evaluating the effect on different cognitive aspects [7]. While some studies suggest that cognitive rehabilitation could improve quality of life, memory, fatigue, depression, and attention, others report negative findings [4, 7, 13–15]. Therefore, there is still a need to investigate it more.

In addition to cognitive rehabilitation, pharmacological interventions are also studied here. It is yet to be cleared whether these approaches are superior to one another. Here, we aimed to assess the effect of cognitive rehabilitation and donepezil therapy on memory, attention, quality of life, and depression among patients with multiple sclerosis compared to two control groups, one receiving placebo and the other one not receiving any intervention. Our main goal was to find out which intervention is superior to other options.

2. Methods

2.1. Study Population. The current study is a prospective study on subjects from two parallel double-blind randomized clinical trials (one published [16] and one in copyediting) conducted on 80 patients referred to Multiple Sclerosis Clinic of Kashani Hospital, affiliated to Isfahan University of Medical Sciences, in 2018. The eligibility criteria were patients ≥18 years with the diagnosis of MS based on the McDonald criteria [17], with Expanded Disability Status Scale (EDSS) [18] ≤5.5, mild/moderate memory impairment (assessed in the screening phase using the questionnaires explained below), who were able to read and write. Eligible subjects were invited to participate in the screening phase by completing everyday memory questionnaire 28-item scale [19] and Beck depression inventory [20] to assess their cognitive ability and depression state. Patients were excluded if they had severe memory impairment (assessed by questionnaires in the screening phase explained below), severe depression, other neurological disorders, history of using AChEIs or psychostimulants, abnormal hepatic or kidney function, current use of anticholinergic medications, or known psychiatric illnesses. We should note that patients needed visual and auditory abilities to complete some tests, so those with severe visual or auditory deficiencies were not included in the study.

2.2. Sample Size and Recruitment. At the power of 80% and a significance level of 0.05, 20 patients were calculated to be included in each group. Written informed consent was obtained from all participants prior to the screening phase. The study was approved by the ethics committee of Isfahan University of Medical Sciences (registration code: 398611) and was registered in the Iranian registry of clinical trials http://clinicaltrials.gov/ct2/show/IRCT201604227522N1.

2.3. Study Protocol. This study was conducted along with two larger studies (donepezil versus placebo and cognitive rehabilitation versus control). Given the calculated sample size, groups of 20 subjects were randomly selected from larger groups in parallel studies. For the larger studies, participants have been randomly assigned to study groups using random allocation software. On those parallel studies, a unique number was assigned to each subject and they were grouped based on those numbers. Numbers were previously divided between study groups. Both patients and interviewers were blinded to the randomization status. The study groups in the current study were group A (cognitive rehabilitation), group B (control without intervention, called control in this manuscript), group C (donepezil treatment), and group D (placebo, called placebo in this manuscript).

Patients were asked to complete the following questionnaires prior to intervention: Abbreviated Mental Test (AMT) [21], Prospective and Retrospective Memory Questionnaire (PRMQ) [22], Multiple sclerosis Quality of Life 54 (MQOL54) [23], and digit span test for attention assessment [24]. Also, they had completed the everyday memory questionnaire 28-item scale [19] and Beck depression inventory [20] in the screening phase as mentioned previously.

In group A, the therapeutic intervention was 10 sessions of cognitive rehabilitation courses. Each session lasted for 2 hours and was individualized for each case based on impaired function reconstruction and modulation. Sessions were held every 7–10 days. Generally, in each class, the therapist aimed for reinforcement and/or consolidation of previous cognitive abilities which have been impaired and tried to reinforce other remained abilities for compensation of impaired abilities. In this way, patients could rehabilitate their role in society and actively maintain their functions [12].

In group C received 10 mg of donepezil (Yasna®, KRKA pharmaceutical company, Slovenia) daily for three months. Patients in group D received placebo pills daily for three months. Placebo pills were similar to donepezil tablets in shape, color, and packaging (Pharmacy Faculty; Isfahan University of Medical Sciences). Patients in group B did not receive any intervention but were followed for three months like other groups.

At the end of the intervention, patients were asked to complete all the questionnaires again. Of note, all patients continued their disease-modifying MS treatment during the study.

2.4. Questionnaires. The Persian version of AMT includes 10 questions that evaluate cognitive impairment. The questions ask for age, orientation for time, date, and place, occupation,
date of birth, questions about the country, invert counting, and repeating an address. The reliability of this test determined to be 0.89 PRMQ consisted of 16 items that target different types of memory failure, as well as the resultant frustration. The items are scored on a 5-point scale (1–5) with higher scores accounting for more frequent memory failures. The reliability of the Persian version is reported to be 0.80 for the Persian version [22]. Everyday memory questionnaire consists of 28 items, and each item scores from 1 to 9. The higher the score, the more the memory dysfunction. This questionnaire assesses patients’ memory during the recent six months. Its Persian version was validated by Sharifi et al. in 2007 [25].

MSQOL consisted of 54 questions assessing physical health, role limitation due to physical and emotional problems, pain, emotional well-being, energy, health perception, social function, cognitive function, health distress, sexual function, and overall quality of life. The higher total scores demonstrate better quality of life in the target subset of the questionnaire. The reliability of the Persian version is reported to be 0.96 [23].

Digit span test evaluates working memory and attention by asking the patients to repeat a list of digits that is being read for them. Higher scores show a greater number of numbers and, therefore, better working memory function [26].

The secondary outcomes were quality of life and depression. The primary outcome was cognitive function, measured by EMQ, AMT, PRMQ, and “digit span test”. We powered the study for digit span test results, but it could also be applied to other questionnaires on cognitive function. The secondary outcomes were quality of life and depression, measured by MSQOL and BDI, respectively.

2.7. Study Analysis. Descriptive data were presented in mean and frequency (%). After assessing data in each category/group for normality of distribution, appropriate statistical tests were selected. We used a paired t-test or Wilcoxon signed-rank test to compare interval variables in the same groups before and after the intervention. Multivariate analysis of covariance (MANCOVA) was used to compare scores after intervention between study groups with adjustment for the baseline data. We also used a post hoc test of Bonferroni in case of any observed differences.

We should note that the samples from two parallel studies were statistically comparable to each other, because the studies were designed with a similar methodology, had similar timing, and looked for similar outcome measures. We carried out statistical analysis using SPSS version 24 (Armonk, NY). A P value of less than 0.05 was considered significant.

3. Results

As stated before, we selected twenty subjects in each group from the pool of patients gathered in this study and two parallel substudies. Baseline data of patients in four study groups are summarized in Table 1. We found no statistically significant difference between groups with regard to demographic features and disease characteristics (duration, disease-modifying agents, dominant symptoms, and annualized relapse rate) (p > 0.05).

Figure 1 demonstrates the mean and standard error (SE) of study questionnaires before and after intervention in four study groups. We found statistically significant improvement with regard to PRMQ, EMQ, QOL (both mental and physical health subscales), and depression in cognitive rehabilitation and donepezil groups (p < 0.001). However, digit span scores improved in the cognitive rehabilitation group only (p < 0.05). Results from MANCOVA are presented in Table 2.

Table 3 shows the post hoc analysis of study tools between groups two-by-two. We found no statistically significant difference comparing pretest and posttest scores between placebo and control groups per post hoc analysis (p > 0.05). Cognitive rehabilitation was superior to donepezil therapy with respect to improving digit span test scores, mental health subscale of quality of life, and depression (p < 0.05). However, both cognitive rehabilitation and donepezil improved EMQ, PRMQ, and physical health subscale of quality of life similarly (p > 0.05). Compared to the placebo and control groups, cognitive rehabilitation improved the outcome in all questionnaires (p < 0.05). But donepezil therapy failed to improve digit span scores.
compared to either placebo or control group, as well as EMQ scores compared to the control group.

With respect to adverse events, two patients in the placebo group reported mild nausea following taking pills. In the donepezil group, two patients reported transient headache, one nausea, and one diarrhea. All symptoms were self-limited.

4. Discussion

Multiple sclerosis affected patients are prone to cognitive impairment; they may also experience conditions such as depression that would additionally affect their quality of life [4, 6]. Decelerating the disease progression and facilitating recovery through medical interventions are necessary to help them overcome the psychological burden of the disease and become motivated to adapt to their new condition and regain their functionality [30]. The latter, however, is not completely achieved through the management of neurological symptoms and may require more interventions focusing on psychological and cognitive impairments.

In the current study, we tried to assess the effectiveness of previously proposed techniques for cognitive impairment compared to each other and control groups. Although memory performance is the most common cognitive function impaired in MS patients [31], we tried to cover other aspects of cognitive and memory function as well by utilizing different questionnaires in the assessment phase. Based on our findings, both cognitive rehabilitation and donepezil therapy successfully improved memory performance, attention, quality of life, and depression, although we found no difference in digit span scores between donepezil and control/placebo groups. Taken together, we can conclude that cognitive rehabilitation is superior to donepezil therapy in regaining function in the mentioned areas.

To explain why donepezil could possibly improve memory function, we should address the major role of the hippocampus in human memory and its neuronal networks rich in cholinergic neurons. With the same mechanism, injuries in muscarinic cholinergic endpoints are responsible for memory disruption in dementia patients [32, 33]. Consequently, donepezil as an AChEI could improve memory function in MS patients as it does in Alzheimer’s Disease. However, it has not always been the case in previous reports. For example, Hughes et al. reported no encouraging outcomes following donepezil therapy in a group of MS patients while they found cognitive rehabilitation to be an effective intervention here [34]. Similarly, Krupp et al. reported no positive effect of donepezil on memory performance [11]. In contrast, some other researchers have claimed a promising outcome of donepezil on memory in MS patients [35, 36]. For example, in another double-

### Table 1: Baseline demographic and clinical characteristics.

|                          | CR n = 20 | Control n = 20 | Donepezil n = 20 | Placebo n = 20 | P value |
|--------------------------|-----------|----------------|------------------|----------------|---------|
| **Demographic characteristics** |           |                |                  |                |         |
| Age, mean ± SD (years)   | 32.2 ± 8.4| 30.6 ± 7.0     | 31.6 ± 6.8       | 30.7 ± 7.4     | 0.89    |
| Education, n (%)         |           |                |                  |                |         |
| High school              | 2 (10)    | 3 (15)         | 3 (15)           | 1 (5)          |         |
| Bachelors                | 15 (75)   | 11 (55)        | 13 (65)          | 14 (70)        |         |
| Postgraduates            | 3 (15)    | 6 (30)         | 4 (20)           | 5 (25)         | 0.810   |
| **Disease characteristics** |           |                |                  |                | 0.969   |
| EDSS, mean ± SD          | 2.67 ± 1.31| 2.55 ± 1.39   | 2.75 ± 1.14      | 2.62 ± 1.32    |         |
| RRMS                     | 16 (80)   | 17 (85)        | 17 (85)          | 18 (90)        | 0.911   |
| SPMS                     | 2 (10)    | 3 (15)         | 2 (10)           | 2 (10)         |         |
| PPMS                     | 2 (10)    | 0 (0)          | 1 (5)            | 0 (0)          |         |
| Disease duration, mean ± SD (years) | 7.20 ± 4.21| 6.65 ± 3.56   | 6.85 ± 3.56      | 5.90 ± 3.27    | 0.697   |
| Interferon beta          | 15 (75)   | 17 (85)        | 16 (80)          | 17 (85)        | 0.875   |
| Fingolimod               | 3 (15)    | 2 (10)         | 3 (15)           | 3 (15)         |         |
| Rituximab                | 2 (10)    | 1 (5)          | 1 (5)            | 0 (0)          |         |
| Annualized relapse rate, n (%) | 0       | 14 (70)        | 16 (80)          | 15 (75)        | 0.983   |
| 1                        | 4 (20)    | 3 (15)         | 4 (20)           | 3 (15)         |         |
| 2                        | 2 (10)    | 1 (5)          | 1 (5)            | 1 (5)          |         |
| Dominant symptoms        |           |                |                  |                |         |
| Motor symptoms           | 9 (45)    | 7 (35)         | 8 (40)           | 8 (40)         | 0.989   |
| Balance symptoms         | 4 (20)    | 4 (20)         | 4 (20)           | 3 (15)         |         |
| Sensory symptoms         | 3 (15)    | 4 (20)         | 4 (20)           | 4 (20)         |         |
| Sphincter symptoms       | 2 (10)    | 2 (10)         | 2 (10)           | 1 (5)          |         |
| Visual symptoms          | 2 (10)    | 3 (15)         | 2 (10)           | 4 (20)         |         |

SD: standard deviation; CR: cognitive rehabilitation, MS: multiple sclerosis, EDSS: Expanded Disability Status Scale; RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.
blinded randomized clinical trial, Krupp et al. showed that a twenty-four-week treatment with donepezil was superior to placebo in the rehabilitation of memory performances [36]. The favorable outcome of cognitive rehabilitation has also been reported on autobiographical memory [37]. Moreover, they found changes in posterior fossa following cognitive rehabilitation, which was also confirmed by Raskin et al. in another study [38]. Also, it is shown that cognitive rehabilitation could improve attention and executive function [39]. Per our findings, we believe that both

| Table 2: Results from multivariate analyses of covariance (MANCOVA) comparing scores of posttests between groups. |
|---------------------------------------------------------------|
| CR estimate (CI 95%) | Control estimate (CI 95%) | Donepezil estimate (CI 95%) | Placebo estimate (CI 95%) | P value |
|----------------------|----------------------------|-----------------------------|--------------------------|---------|
| Everyday memory      | 83.89 (66.9, 100.7)       | 112.84 (92.6, 133.0)       | 93.78 (74.1, 113.4)       | F (3, 70) = 9.93 d\(=\) 0.336, \(P < 0.001\) |
| Prospective and retro prospective memory                    | 35.41 (31.9, 38.8)        | 48.76 (44.6, 52.8)         | 38.22 (34.2, 42.2)        | F (3, 70) = 16.08 d\(=\) 0.45, \(P < 0.001\) |
| Digit span memory                                           | 13.43 (12.6, 14.2)       | 10.77 (9.8, 11.7)          | 11.18 (10.2, 12.1)        | F (3, 70) = 10.41 d\(=\) 0.34, \(P < 0.001\) |
| Physical health                                              | 65.24 (60.4, 70.0)       | 49.99 (44.2, 55.7)         | 60.32 (54.7, 65.8)        | F (3, 70) = 8.44 d\(=\) 0.30, \(P < 0.001\) |
| Mental health                                                | 68.26 (62.1, 74.4)       | 45.43 (38.0, 52.8)         | 56.04 (48.8, 63.2)        | F (3, 70) = 15.58 d\(=\) 0.44, \(P < 0.001\) |
| Depression                                                   | 11.74 (8.7, 14.6)        | 24.27 (20.7, 27.8)         | 18.46 (15.0, 21.9)        | F (3, 70) = 21.82 d\(=\) 0.52, \(P < 0.001\) |

\(a\) Prediction adjusted with baseline covariate model MANCOVA; CR: cognitive rehabilitation; CI 95\%: confidence interval 95\%; d: hesitantly defined effect sizes as “small, \(d = 0.2\),” “medium, \(d = 0.5\),” and “large, \(d = 0.8\),”
Interventions are effective in improving cognitive impairment although cognitive rehabilitation is the superior one. Similar findings have also been reported in other studies [40, 41].

On the other hand, depression is a major complaint of MS patients which is also associated with cognitive impairment; also, it is not well established. For instance, a study reported that frontal lobe functioning is compromised in depressed cases while this lobe is responsible for cognitive performances such as attention, concentration, and information processing [42]. Bruce et al. suggested the association of depression with memory impairment, as well. Comparing MS patients with and without depression, they found that depressed cases estimate their everyday memory in proportion to the actual performance while those without depression overestimate their ability [43]. We also hypothesized that improving cognitive function through cognitive rehabilitation could also improve depression in affected individuals and observed the desired outcome.

Quality of life is another area significantly affected in MS patients. Decreased quality of life occurs due to physical disabilities, long-term duration of disease, fatigue, and depression, as well as other impairments, including memory and cognition [44, 45]. A study by Birnboim et al. showed that cognitive rehabilitation improved MS patients’ quality of life. The authors suggested that the higher self-esteem achieved following rehabilitation is a possible factor in improving quality of life [46].

Comparing the placebo and the control group (not receiving any intervention), we find improved everyday memory and depression in the placebo group. The effectiveness of placebo in psychological problems has been known in various disorders. Although donepezil improved both of these categories compared to placebo, it may still suggest that some observed findings here have been due to the placebo effect.

Our study was limited by the relatively small number of subjects in each group, lack of long-term follow-ups to evaluate the persistency of observed outcomes, and not having groups receiving combined interventions or using cross-over design to assess the effectiveness of interventions more precisely. We randomly selected participants from a larger pool of patients recruited in parallel randomized clinical trials, which would probably not benefit from all strengths of randomized trials. Also, our study lacks an active control group for cognitive rehabilitation. Another limitation is relying on a self-report memory scale to include patients in the study. Moreover, almost all the cognitive measures investigated in this study could be potentially confounded by depression and other psychosocial factors, although we have tried to control for the outcome measures for baseline scores using the appropriate statistical methods. Despite limitations, it presents useful and practical information with respect to cognitive impairment in MS cases, investigating various aspects of cognition at the same time.

### 5. Conclusion

To conclude, both cognitive rehabilitation and donepezil therapy could effectively improve memory performance, attention, depression, and quality of life in MS patients. However, cognitive rehabilitation is superior to donepezil, especially when it comes to depression and digit span memory. We recommend studies on combined methods of intervention in the future.

### Data Availability

Data are available upon request to the corresponding author.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

The authors would like to thank the officials of Multiple Sclerosis Clinic of Kashani Hospital, affiliated to Isfahan University of Medical Sciences, for their support and assistance.
University of Medical Sciences, for their kind help and cooperation during the study implementation. This study was financially supported by Isfahan University of Medical Sciences (grant number: 398611).

References

[1] H. Lassmann, "Multiple sclerosis pathology," Cold Spring Harbor Perspectives in Medicine, vol. 8, no. 3, Article ID a028936, 2018.

[2] D. Amtmann, A. M. Bamer, J. Kim, H. Chung, and R. Salem, "People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by promis and Neuroqol outcome measures," Disability and Health Journal, vol. 11, no. 1, pp. 99–107, 2018.

[3] F. Ashrati, A. Safaee, V. Shaygannejad, M. A. Najafi, and S. Vesal, "Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: a cross-sectional study," Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, vol. 22, 2017.

[4] E. Rosti-Otajärvi, A. Määttänen, K. Koivistio, H. Huhtala, and P. Hääläläinen, "Neuropsychological rehabilitation has beneficial effects on perceived cognitive deficits in multiple sclerosis during nine-month follow-up," Journal of the Neurological Sciences, vol. 334, no. 1-2, pp. 154–160, 2013.

[5] S. B. Patten, R. A. Marrie, and M. G. Carta, "Depression in multiple sclerosis," International Review of Psychiatry, vol. 29, no. 5, pp. 463–472, 2017.

[6] S. A. Berzins, A. G. Bulloch, J. M. Burton, K. S. Dobson, G. H. Fick, and S. B. Patten, "Determinants and incidence of depression in multiple sclerosis: a prospective cohort study," Journal of Psychosomatic Research, vol. 99, pp. 169–176, 2017.

[7] M. Mitolo, A. Venneri, I. D. Wilkinson, and B. Sharrack, "Cognitive rehabilitation in multiple sclerosis," A Systematic Review, vol. 354, no. 1-2, pp. 1–9, 2015.

[8] M. Sharifipour, E. Izadpanah, B. Nikkhoo et al., "A new pharmacological role for donepezil: attenuation of morphine-induced tolerance and apoptosis in rat central nervous system," Journal of Biomedical Science, vol. 21, no. 1, p. 6, 2014.

[9] T. Niitsu, H. Hashimoto, "Sigm-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases," Current Pharmaceutical Design, vol. 18, no. 7, pp. 875–883, 2012.

[10] C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, L. E. Elkins, and L. B. Krupp, "Effects of donepezil on memory and cognition in multiple sclerosis," Journal of the Neurological Sciences, vol. 245, no. 1-2, pp. 127–136, 2006.

[11] L. B. Krupp, C. Christodoulou, P. Melville et al., "Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis," Neurology, vol. 76, no. 17, pp. 1500–1507, 2011.

[12] K. D. Cicerone, D. M. Langenbahn, C. Braden et al., "Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008," Archives of Physical Medicine and Rehabilitation, vol. 92, no. 4, pp. 519–530, 2011.

[13] H. Hildebrandt, M. Lanz, H. K. Hahn et al., "Neuroscience, cognitive training in MS: effects and relation to brain atrophy," Restor Neurology Neuroscience, vol. 25, no. 1, pp. 33–43, 2007.

[14] N. B. Lincoln, A. Dent, J. Harding et al., "Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis," Journal of Neurology, Neurosurgery & Psychiatry, vol. 72, no. 1, pp. 93–98, 2002.

[15] A. Plohmann, L. Kappos, and H. Brunnschweiler, "Evaluation of a computer-based attention retraining program for patients with multiple sclerosis," Schweizer Archiv Fur Neurologie und Psychiatrie (Zurich, Switzerland: 1985), vol. 145, no. 3, p. 35, 1994.

[16] M. M. Shahpouri, M. Barekatain, M. Tavakoli, S. Sanaei, and V. Shaygannejad, "Evaluation of cognitive rehabilitation on the cognitive performance in multiple sclerosis: a randomized controlled trial," Journal of Research Medical Science, vol. 24, no. 110, 2019.

[17] A. J. Thompson, B. L. Banwell, F. Barkhof et al., "Diagnosis of multiple sclerosis," Revisions of the McDonald Criteria, vol. 17, no. 2, pp. 162–173, 2017.

[18] J. F. Kurtzke, "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)," Neurology, vol. 33, no. 11, p. 1444, 1983.

[19] J. Royle and N. B. Lincoln, "The everyday memory questionnaire-revised: development of a 13-item scale," Disability and Rehabilitation, vol. 30, no. 2, pp. 114–121, 2008.

[20] H. Ghassemzadeh, R. Mojtahib, N. Karamghadiri, and N. Ebrahimkhani, "Psychometric properties of a Persian-language version of the Beck depression inventory - second edition: BDI-II-Persian," Depression and Anxiety, vol. 21, no. 4, pp. 185–192, 2005.

[21] F. Bakhtiyari, M. Foroughian, H. Fakhrzadeh et al., "Validation of the persian version of abbreviated mental test (AMT) in elderly residents of Kahrizak charity foundation," Iranian Journal of Diabetes and Metabolism, vol. 13, no. 6, pp. 487–494, 2014.

[22] H. Zare, M. Sahragard, and S. Khodamoradi, "Investigating of internal consistency and confirmatory factor Analysis of prospective and retrospective memory in an Iranian sample," Iranian Journal Of Cognition And Education, vol. 1, no. 1, pp. 33–38, 2014.

[23] H. Ghaem, A. Haghighi, P. Jafari, and A. Nikseresht, "Validity and reliability of the Persian version of the multiple sclerosis quality of life questionnaire," Neurology India, vol. 55, no. 4, p. 369, 2007.

[24] V. Planche, M. Gibelin, D. Cregut, B. Pereira, and P. Clavelou, "Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing–remitting, secondary progressive and primary progressive multiple sclerosis," European Journal of Neurology, vol. 23, no. 2, pp. 282–289, 2016.

[25] M. Sharifi, H. T. Neshatdoust, M. Tavakoli, and V. Shaygannejad, "Investigating the effects of depression on retrospective, everyday and prospective memory in patients with multiple sclerosis," Advances in Cognitive Science, vol. 18, no. 3, pp. 18–26, 2016.

[26] V. Shaygannejad, M. Janghorbani, F. Ashrati, H. A. Zanjani, and N. Zakizade, "Effects of rivastigmine on memory and cognition in multiple sclerosis," Canadian Journal of Neurological Sciences/Journal Canadien des Sciences Neurologiques, vol. 35, no. 4, pp. 476–481, 2008.

[27] R. J. Greenwood, T. M. McMillan, M. P. Barnes, and C. D. Ward, Handbook of Neurological Rehabilitation, Psychology Press, London, UK, 2005.

[28] B. A. Wilson, Neuropsychological rehabilitation," Annual Review of Clinical Psychology, vol. 4, no. 1, pp. 141–162, 2008.

[29] B. A. Wilson, Memory Rehabilitation: Integrating Theory and Practice, Guilford Press, New York, NY, USA, 2009.

[30] S. Babaei, Z. Shafei, M. M. Sadeghi, A. Y. Nik, and M. Valiani, "Effectiveness of massage therapy on the mood of patients
after open-heart surgery,” *Iranian Journal of Nursing and Midwifery Research*, vol. 17, no. 2 Suppl 1, p. S120, 2012.

[31] K. Ebrahimzade, L. Sepas, R. Yazdan-Panah, M. Abedi Ghelich Gheshlaghi, and M. GHasabi-Alamdari, “Working memory and quality of life in multiple sclerosis patients,” *The Journal of Urmia University of Medical Sciences*, vol. 27, no. 7, pp. 598–607, 2016.

[32] S. A. Bunge, K. N. Ochsner, J. E. Desmond, G. H. Glover, and J. D. Gabrieli, “Prefrontal regions involved in keeping information in and out of mind,” *Brain*, vol. 124, no. 10, pp. 2074–2086, 2001.

[33] M. E. Hasselmo, “The role of acetylcholine in learning and memory,” *Current Opinion in Neurobiology*, vol. 16, no. 6, pp. 710–715, 2006.

[34] A. J. Hughes, K. M. Dunn, and T. Chaffee, “Sleep disturbance and cognitive dysfunction in multiple sclerosis: a systematic review,” *Current Neurology and Neuroscience Reports*, vol. 18, no. 1, p. 2, 2018.

[35] J. Cotter, N. Muhlert, A. Talwar, and K. Granger, “Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: a systematic review and meta-analysis,” *Neuroscience & Biobehavioral Reviews*, vol. 86, pp. 99–107, 2018.

[36] L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins, “Donepezil improved memory in multiple sclerosis in a randomized clinical trial,” *Neurology*, vol. 63, no. 9, pp. 1579–1585, 2004.

[37] N. D. Chiaravalloti, H. M. Genova, and J. DeLuca, “Cognitive rehabilitation in multiple sclerosis: the role of plasticity,” *Frontiers in Neurology*, vol. 6, p. 67, 2015.

[38] S. A. Raskin and M. M. Sohlberg, “Prospective memory intervention: a review and evaluation of a pilot restorative intervention,” *Brain Impairment*, vol. 10, no. 1, pp. 76–86, 2009.

[39] M. Flavia, C. Stampatori, D. Zanotti, G. Parrinello, and R. Capra, “Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis,” *Journal of the Neurological Sciences*, vol. 288, no. 1-2, pp. 101–105, 2010.

[40] N. D. Chiaravalloti, J. DeLuca, N. B. Moore, and J. H. Ricker, “Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial,” *Multiple Sclerosis Journal*, vol. 11, no. 1, pp. 58–68, 2005.

[41] S. H. Pierson and N. Griffith, “Treatment of cognitive impairment in multiple sclerosis,” *Behavioural Neurology*, vol. 17, no. 1, pp. 53–67, 2006.

[42] E. Shevil and M. Finlayson, “Process evaluation of a self-management cognitive program for persons with multiple sclerosis,” *Patient Education and Counseling*, vol. 76, no. 1, pp. 77–83, 2009.

[43] J. M. Bruce and P. A. Arnett, “Self-reported everyday memory and depression in patients with multiple sclerosis,” *Journal of Clinical and Experimental Neuropsychology*, vol. 26, no. 2, pp. 200–214, 2004.

[44] N. Chehreh-Negar, F. Shams, S. Zarshenas, and A. Nikseresht, “Correlation between working memory and quality of life in multiple sclerosis patients,” *Feyz Journals of Kashan University of Medical Sciences*, vol. 16, no. 4, 2012.

[45] M. Barzegar, S. Badihian, O. Mirmosayyeb et al., “Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: the first report from Iran,” *Multiple Sclerosis and Related Disorders*, vol. 22, pp. 161–165, 2018.

[46] S. Birnboim and A. Miller, “Cognitive rehabilitation for multiple sclerosis patients with executive dysfunction,” *Multiple Sclerosis Journal*, vol. 10, no. 1, pp. 67–73, 2004.